NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio

Executive Summary

• NetraMark Holdings announced that its peer‑reviewed paper on the NetraAI platform has been accepted for publication in npj Digital Medicine (Nature Portfolio).
• The study demonstrates how NetraAI can identify interpretable patient subpopulations (“Personas”/MDS) to improve precision enrichment in a Phase II ketamine trial for treatment‑resistant depression.
• Company executives highlighted the significance of explainable AI for regulatory science and clinical‑trial design.

Key Details

• Publication: “Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial,” accepted by npj Digital Medicine.
• Data Source: National Institute of Mental Health (NIMH) Phase II ketamine trial in treatment‑resistant depression.
• Key Findings: NetraAI uncovered interpretable “Personas” that may guide precision‑enrichment strategies across psychiatry and other therapeutic areas; integration of dynamical‑systems modeling, long‑range‑memory feature learning, and LLM explainability improves decision‑making and reduces placebo interference.
• Co‑authors: Researchers from NIMH (Dr. Elizabeth D. Ballard, Dr. Carlos A. Zarate Jr.) plus NetraMark scientists and academic collaborators.
• Executive Comments:
• Dr. Joseph Geraci (Chief Scientific & Technical Officer) – emphasized the paper’s role in validating the AI engine for clinical trials.
• Dr. Luca Pani (Chief Innovation & Regulatory Officer) – noted the importance of explainability, reproducibility, and traceability for regulators and investigators.
• Access: Full article available at https://www.nature.com/articles/s41746-025-02143-7.

Notable Quotes

“Acceptance of this paper for publication by npj Digital Medicine affirms the progress we’ve made toward building an AI engine purpose‑built for clinical trials.” – Dr. Joseph Geraci, CSO & CTO

“This publication bridges scientific innovation with the rigorous expectations of regulatory science…provides regulators and clinical investigators with credible tools designed to support modern clinical trial design and decision‑making.” – Dr. Luca Pani, Chief Innovation and Regulatory Officer